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Hodgkin lymphoma (HL) is one of the most common malignancies in young adults and has become a curable malignancy for most 
patients in recent decades.1,2 However, many controver-
sies still exist on the optimal strategy of how to cure pa-
tients. The key question is how to balance the risks and 
toxicities of chemotherapy and radiotherapy against the 
need for a definite treatment for early or advanced-stage 
HL patients.3
The observation that patients suffering from early 
stage HL have a worse prognosis when certain clinical 
risk factors were present and thus need a more inten-
sive therapy, lead to the definition of two prognostic 
groups: early favorable without clinical risk factors and 
early unfavorable with clinical risk factors. The defini-
tion of clinical risk factor is overlapping but not iden-
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BACKGROUND AND OBJECTIVES: Whether it is possible to reduce the intensity of treatment in early (stage 
i or ii) hodgkin lymphoma with a favorable prognosis remains unclear. therefore, we conducted this random-
ized trial, comparing two treatment groups consisting of a combination chemotherapy regimen of two different 
intensities followed by involved-field radiation therapy at two different dose levels. 
DESIGN AND SETTING: Prospective, randomized, in patients referred to the Department of Clinical oncology 
and nuclear medicine. 
PATIENTS AND METHODS: ninety-eight patients with histologically proven early-stage hodgkin lymphoma 
with a favorable prognosis were enrolled in this study between January 2008 and June 2010. they were ran-
domly assigned in one of two treatment arms: arm i received four cycles of aBVD (adriamycin, belomycin, 
vinblastine, dacarbazine) followed by 30 Gy of involved-field radiation therapy; arm ii received two cycles of 
aBVD followed by 20 Gy of involved-field radiation therapy. 
RESULTS: During the follow-up period, the 2-year relapse free survival rates were 96% and 95% in arm i and 
arm ii, respectively(P=.8), while the 2-year overall survival rates were 98% and 95% in arm i and arm ii, re-
spectively (P=.16). acute toxicity affected 54% of patients treated with four cycles of aBVD, who had grade iii 
or iV toxicity, as compared with 30% of those receiving two cycles (P<.02). the rates of acute toxicity (grade iii 
or iV) were also higher among patients treated with 30 Gy of involved-field radiation therapy than among those 
receiving 20 Gy (16% vs. 2.5%, P<.03) . 
CONCLUSION: in patients with early-stage hodgkin lymphoma and a favorable prognosis, treatment with two 
cycles of aBVD followed by 20 Gy of involved-field radiation therapy was as effective as, and less toxic than, 
four cycles of aBVD followed by 30 Gy of involved-field radiation therapy.
tical in major study groups. In the German Hodgkin 
Study Groups (GHSG) trials, the risk factors are large 
mediastinal mass, extranodal disease, involvement of 3 
or more nodal areas and ESR ≥50 without B symptoms 
or ≥30 with B symptoms.4,5
For early-stage favorable HL, extended-field radio-
therapy (EFRT) has been considered as standard treat-
ment for more than two decades. However, EFRT has 
been abandoned by most study groups due to the rec-
ognition of late effects such as heart failure, pulmonary 
dysfunction, and secondary malignancies.6,7 Instead, 
four cycles of ABVD followed by 30 Gy of involved-
field radiation therapy are now regarded as the stan-
dard of care by many groups.8 While consolidation ra-
diotherapy is part of treatment for patients with early 
stage Hodgkin lymphoma in the European Society 
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of Medical Oncology (ESMO) clinical recommenda-
tions,9 the National Comprehensive Cancer Network 
(NCCN) guidelines consider chemotherapy alone an 
alternative treatment option.10
Depending on intensity and dose of treatment, long-
term complications such as secondary malignancis, 
cardiac disease and infertility are common in Hodgkin 
survivors.9,11,12 In an attempt to reduce the toxic effects 
of treatment while retaining full control of the cancer, 
GHSG concluded from the results of a prospective, 
randomized, multicenter study (HD10) that patients 
with early- stage HL with a favorable prognosis, treat-
ment with two cycles of ABVD (Adriamycin, belomy-
cin, vinblastine, dacarbazine) followed by 20 Gy of in-
volved-field radiation therapy is as effective as, and less 
toxic than, four cycles of ABVD followed by 30 Gy of 
involved-field radiation.13
The aim of this study was to determine whether few-
er cycles of chemotherapy and lower doses of radiation 
therapy could be delivered to reduce the toxic effects of 
treatment, while maintaining high rates of disease con-
trol in patients with early Hodgkin lymphoma with a 
favorable prognosis who were undergoing combined- 
approach treatment programs.
PATIENTS AND METHODS
Between January 2008 and June 2010, 98 patients with 
newly diagnosed Hodgkin lymphoma in clinical stage 
I or II with a favorable prognosis who attended the 
Clinical Oncology and Nuclear Medicine Department, 
Mansoura University Hospital, Mansoura, Egypt, were 
randomly assigned in this prospective study. Eligibility 
criteria included males and females older than 18 
years, with an Eastern Cooperative Oncology Group 
(ECOG) performance status 0-1, histologically proven 
Hodgkin lymphoma in clinical stage I or II, with no 
clinical risk factors; B symptoms (fever ≥38°C, soak-
ing night sweats, weight loss ≥10% within 6 months), 
extranodal disease, bulky disease (≥10 cm or >33% of 
the chest diameter on chest x-ray), three or more sites 
of nodal involvementand or a sedimentation rate of 50 
or more, and no evidence of coexistent synchronous or 
previous malignant disease, previous radiotherapy, pre-
vious chemotherapy or previous surgery except biopsy 
only.
Pretreatment evaluation included a medical his-
tory, physical examination, complete blood work, elec-
trocardiogram and neck, chest, abdominal and pelvic 
computed tomography (CT). Patients who fulfilled the 
above eligibility criteria were made aware of the pur-
pose and the design of the study and required to sign 
the informed consent. Eligible patients were randomly 
assigned into two treatment arms. Arm I (n=50 pa-
tients) was treated by four cycles of ABVD followed by 
30 Gy of involved-field radiation therapy. Arm II (n=48 
patients) were treated by two cycles of ABVD followed 
by 20 Gy of involved-field radiation therapy.
ABVD was administered on days 1 and 15 in 
monthly cycles, at the following standard doses: doxo-
rubicin, 25 mg per square meter of body surface area; 
bleomycin, 10 mg per square meter; vinblastine, 6 mg 
per square meter; and dacarbazine, 375 mg per square 
meter. If the white-cell count was less than 2500 per cu-
bic millimeter or the platelet count was less than 80 000 
per cubic millimeter on a day when chemotherapy was 
scheduled to be administered, treatment was post-
poned until normal levels were achieved. Granulocyte 
colony-stimulating factor was given if clinically indicat-
ed. During treatment, the patients were examined for 
acute toxicity every week. Toxicities were graded using 
the WHO Toxicity Criteria.14
Before treatment, all sites of disease were defined 
and documented. Patients were treated with external 
beam irradiation by a 6 MV linear accelerator planned 
as involved-field radiation according to the sites of dis-
ease. The recommended interval between completion of 
the ABVD regimen and the start of radiation therapy 
was 4 to 6 weeks. Patients received either 30 Gy or 20 
Gy of involved-field radiation therapy in single frac-
tions of 1.8 to 2.0 Gy administered five times weekly.
Response was assessed six weeks after comple-
tion of radiotherapy by clinical examination and neck, 
chest, abdominal and pelvic CT. Criteria for response 
were as follows: complete response (CR) was defined 
as complete regression of all evidence of tumor. Partial 
response (PR) was defined as an estimated decrease in 
tumor size of 50% or more. Stationary disease (SD) 
was defined as <50% decrease in tumor size or <25% 
increase in pretreatment tumor size. Progressive disease 
(PD) was defined as > 25% increase in pretreatment 
tumor size. Re-evaluation was done at 3 months inter-
val during the first two years of follow-up. The primary 
efficacy end point was relapse-free survival. Overall sur-
vival and treatment toxicity were secondary end points
All data were categorical and represented as number 
and percent. The baseline characteristics and adverse ef-
fects of the two treatment arms were compared using 
the Chi-square test. Confidence intervals (CIs) were 
calculated using the Cox proportional hazard model. 
Overall survival and relapse free survival for the two 
groups were calculated using the Kaplan-Meier meth-
od. Informed consent was obtained from all patients, 
and ethical committee approval was received by our 
participating center. The randomization scheme was a 
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permuted block design with an equal probability of as-
signment to either treatment arms. Patients were strati-
fied by primary site of disease and stage of disease and 
were then randomized to receive one of the two treat-
ments planned in the trial.
RESULTS
From January 2008 to June 2010, 98 patients were 
recruited and randomly assigned into two treatment 
arms, either arm 1 with 50 patients or arm II with 48 
patients. In arm II, 8 patients were excluded from all 
analyses: 2 becuase of incorrect initial staging, 2 who 
could not subsequently be contacted and 4 who refused 
the reduced treatment regimen after randomization. A 
total of 90 patients received complete treatment as de-
fined per protocal or with an acceptable variation.
The baseline characteristics of the study patients 
are shown in Table 1. No significant differences were 
noted between treatment arms for any of the charac-
teristics. The median age of patients at randomization 
was 26 years (range, 18 to 44), and 66.7% were male. 
Table 1. Characteristics of 90 patients with early stage Hodgkin lymphoma by treatment arm.
Character
Total Arm I Arm II
P
No. % No. % No. %
Age (years)
   <30 78 86.7 40 80 38 95
.0590
   ≥30 12 13.3 10 20 2 5
Sex
   Male 60 66.7 32 64 28 70
.6542
   Female 30 33.3 18 36 12 30
Site
   Supradiaphragmatic 80 88.9 42 84 38 95
.1754
   infradiaphragmatic 10 11.1 8 16 2 5
Histologic type
   Mixed cellularity 28 31.1 16 24 12 30
.8353
   nodular sclerosing 42 46.7 22 44 20 50
   lymphocyte-rich 20 22.2 12 32 8 20
   lymphocyte-depleted 0 0 0 0 0 0
Ann Arbor stage
   i a 50 55.6 24 48 26 65
.6889
   i B 10 11.1 6 12 4 10
   ii a 26 28.9 16 32 10 25
   iiB 4 4.4 2 4 2 5
 
Infradiaphragmatic disease was present in 11.1%. The 
most frequent subtype diagnosed by the pathology 
reference panel was nodular sclerosing (46.7%). Ann 
Arbor staging was 55.6% for stage IA disease, 11.1% 
for stage IB, 28.9% for stage IIA, and 4.4% for stage 
IIB. Response assessment was done 4-6 weeks after the 
completion of treatment. All patients achieved a clini-
cal complete response (CR) or CR unconfirmed in both 
arms.
Acute toxicity during chemotherapy was more fre-
quent in patients who received four cycles of ABVD 
than in those who received two cycles (Table 2). 
Overall, 54% of the patients who received four cycles 
of ABVD had at least one instance of severe toxicity 
(grade III or IV) as compared with 30% of those who 
received two cycles (P=.02).  The most frequent events 
were hair loss (in 28% of patients receiving four cycles 
vs. 15% of those receiving two cycles) and hematologic 
toxic effects (28% vs. 10%). Infections and pulmonary 
fibrosis were also more common with four cycles of 
ABVD than with two cycles (4% vs. 0%)for each of 
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them. Severe toxicity (grade III or IV) was observed 
more often among the patients treated with 30 Gy of 
involved-field radiation therapy than among those who 
received 20 Gy (16% vs. 2.5%, P=.03). The most com-
mon sites of grade 3 or worse acute side effects were the 
skin , the mucous membranes and the pharynx. Acute 
toxicity was higher in arm I but was tolerable and man-
ageable.
The relapse rate was 4.4 % (4 of 90). No significant 
differences were seen in rates of relapse in either arm. 
The rates of relapse-free survival in the whole analysis 
set of 90 patients were estimated to be 95.6% (95% CI: 
89.1 to 98.2) at 2 years.
The overall survival rates for all 90 patients were 
estimated to be 96.7 % (95% CI: 90.7 to 98.8) at 2 
years. The median observation time for the primary end 
point, relapse-free survival, was identical in the two che-
motherapy arms (28 months). Relapse free survival at 2 
years was 96% in arm I (95% CI: 86.5 to 98.8) and 95% 
with arm II, (95% CI: 83.4 to 98.5) with no statisti-
cally significant difference (P=.8) . Results of Kaplan- 
Meier estimates of relapse free survival in both treat-
ment arms are shown in Figure 1. At a median follow-
up of 30 months of all analyzed patients, the median 
overall survival in armI was 28 months, ranging from 
14 to 39 months vs 27 months, ranging from 12 to 39 
months in arm II, with no statistically significant differ-
ence (P=.16) The 2-year overall survival in arm I was 
98% (95% CI: 88.5 to 99.8) vs 95% (95% CI: 83.4 to 
98.5) in arm II, with no statistically significant differ-
ence (P=.43) (Figure 2).
A total of 3 patients died during the follow-up pe-
riod. The causes of death were toxicity of primary ther-
apy in one patient treated with four cycles of ABVD 
(died from pneumonia), toxicity of salvage therapy in 
one patient assigned to two cycles of ABVD (died from 
sepsis) and not specified in one patient assigned to arm 
II.
DISCUSSION
One of the key objectives in the treatment of Hodgkin 
lymphoma is to reduce the intensity of first-line therapy 
as much as possible while maintaining tumor control. 
This is most relevant for early disease with a favorable 
prognosis, which accounts for about 30% of all cases of 
Hodgkin lymphoma.15 In our study, the results showed 
noninferiority for both fewer cycles of chemotherapy 
and a lower dose of radiation, in comparison with more 
intensive treatment . No difference in efficacy was noted 
between both arms. This was true for the primary end 
point of relapse-free survival at 2 years that was 96% 
in arm I (95% CI: 86.5 to 98.8) and 95% in arm II, 
Table 2.  acute adverse effects (grade iii or iv) in both treatment arms.
Event
Arm I Arm II
No. % No. %
anemia 2 4 0 0
Thrombopenia 2 4 0 0
leukopenia 12 24 4 10
nausea or vomiting 6 12 4 10
Pulmonary fibrosis 2 4 0 0
Hair loss 14 28 6 15
infection 2 4 0 0
Skin toxicity
(dermatitis) 2 4 0 0
Mucous membrane
(mucositis) 4 8 1 2.5
Pharynx /esophagus
(dysphagia) 2 4 0 0
Figure 1. relapse-free survival in the two treatment arms.
(95% CI:83.4 to 98.5) with no statistically significant 
difference (P=.8). For all other efficacy end points, such 
as response there was no statistically significant differ-
ence. Similar results were confirmed by a large clinical 
trial by the German Hodgkin Study Group (GHSG). 
GHSG HD10 compared four cycles with two cycles of 
ABVD; both followed either 30 or 20 Gy RT, respec-
tively. Importantly, the weakest combination was not 
inferior to any other combination. Thus, two cycles of 
ABVD, followed by 20 Gy IFRT, are the new treat-
ment standard for early favorable HL patients.11,13 In 
our study, the relapse rate was only 4% (4 of 90). in the 
original research report BrieF TreaTMenT HOdgKin lYMPHOMa
Hematol Oncol Stem Cell Ther 5(1)     First Quarter 2012 hemoncstem.edmgr.com40
same context Sieniawski et al8 reported the same per-
centage among 1129 patients with early-stage favorable 
Hodgkin lymphoma enrolled onto the HD7/HD10/
HD13 trials of the German Hodgkin Study Group. 
Forty-two patients (3.6 %) had treatment failure. 
In terms of treatment complications, in our study, 
two cycles of ABVD as well as 20 Gy of radiation re-
sulted in reduced rates of acute toxicity. Overall, 54% 
of patients treated with four cycles of ABVD had grade 
III or IV toxicity, as compared with 30% of those who 
received two cycles (P<.02). The rates of acute toxicity 
(grade III or IV) were also higher among patients treat-
ed with 30 Gy of involved-field radiation therapy than 
among those received 20 Gy (16% vs. 2.5%, P<.03). in 
the same context Connors,16 Yahalom17 and Nachman18 
reported that a shorter chemotherapy regimen with a 
lower radiation dose preserves a high level of disease 
control with lower toxicity.
Clearly, longer follow-up is needed to identify long-
term toxicity, such as secondary neoplasm and severe 
organ damage. Given that many of the late, fatal com-
plications of radiation therapy do not emerge until the 
second decade after treatment, our study cannot speak 
to the effect of treatment on overall survival. As the 
follow-up is short differences may appear with a longer 
duration of follow-up, so these results are considered 
preliminary and reanalysis is planned after another 3 
years.
Currently, risk factors do not allow identification of 
patients who can be cured with even less treatment. The 
use of positron-emission tomography (PET) might 
help to discriminate between patients at low risk and 
those at high risk. Several ongoing trials are evaluat-
ing the role of PET in identifying patients with early 
Hodgkin lymphoma and a favorable prognosis who 
might not need additional radiation therapy after a brief 
chemotherapy course.19-21
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Figure 2. Overall survival in the two treatment arms.
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